HeartFlow's Path to Profitability Looks Clearer Than Before, If Revenue Acceleration Holds

HeartFlow Inc (HTFL) reports second-quarter 2026 earnings after market close on August 13, 2026, with analysts expecting continued losses but significant year-over-year improvement. The central question is whether the medical technology company can sustain its strong revenue growth trajectory while narrowing losses faster than expected. With the stock trading near analyst price targets and technical momentum building, the earnings release will test whether HTFL's AI-powered cardiac imaging platform can deliver on its commercial promise.

Part 1: Earnings Preview

HeartFlow develops non-invasive AI-powered cardiac imaging technology that analyzes coronary artery disease, offering physicians a diagnostic alternative to invasive procedures. The company's FFR-CT technology has gained traction in the healthcare market as it expands its commercial footprint and reimbursement coverage.

Analysts expect HTFL to report a loss of $-0.22 per share for Q2 2026, with revenue estimates ranging from $56.47M to $57M according to consensus forecasts. The company most recently reported Q1 2026 earnings of $-0.23 per share. Compared to the same quarter last year when HTFL posted a loss of $-1.46 per share, the consensus estimate represents an 84.93% improvement year-over-year, signaling substantial progress in the company's path toward profitability.

Three key themes define this earnings story:

Commercial Execution and Revenue Growth: HTFL has demonstrated strong top-line momentum with revenue growth exceeding 30% year-over-year in recent quarters. Investors will scrutinize whether the company can maintain this trajectory as it scales its commercial operations and expands market penetration for its FFR-CT technology. The guidance range of $228M-$232M for full-year 2026 suggests management confidence in sustained growth.

Path to Profitability: The dramatic improvement in losses from $-1.46 per share a year ago to an expected $-0.22 this quarter reflects HTFL's improving unit economics and operational leverage. Analysts are watching closely to see if the company can continue narrowing losses while investing in growth, with full-year 2026 loss estimates of $-0.82 per share representing a 59% improvement from 2025.

Reimbursement Expansion and Market Adoption: As a medical technology company, HTFL's success hinges on expanding insurance reimbursement coverage and physician adoption. Recent quarters have shown progress on both fronts, and investors will look for updates on new payer agreements, utilization trends, and international expansion efforts that could accelerate the path to sustainable profitability.

Analyst commentary ahead of the release has been constructive, with 8 of 10 analysts rating the stock a Strong Buy and sentiment improving over the past month. The consensus view suggests HTFL is executing well on its commercial strategy, though questions remain about the pace of margin improvement and the timeline to breakeven.

Part 2: Historical Earnings Performance

HeartFlow's recent earnings history reveals a company in transition, with volatile results gradually giving way to more consistent performance. Over the past four quarters, HTFL has delivered two beats and two misses against analyst estimates, though the magnitude of surprises has moderated significantly.

The most dramatic result came in Q2 2025, when HTFL reported a loss of $-1.46 per share against expectations of $-0.20, a -630% miss that shocked investors. This outlier appears to have been driven by one-time factors, as subsequent quarters showed marked improvement. Q3 2025 brought another miss at $-0.35 versus $-0.27 expected (-29.63% surprise), but the company then pivoted to positive surprises in the following two quarters. Q4 2025 delivered a +25% beat with $-0.18 reported versus $-0.24 expected, and Q1 2026 came in at $-0.23 against $-0.24 estimates for a modest +4.17% beat.

The trend suggests HTFL is gaining better visibility into its financial performance and managing expectations more effectively. The company has moved from massive misses to narrow beats, indicating improved operational predictability as the business matures. However, the pattern also shows HTFL remains in a loss-making phase where small changes in revenue recognition, operating expenses, or one-time items can swing results significantly relative to estimates.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

HeartFlow typically reports earnings after market close, meaning Day 0 reflects pre-announcement anticipation while Day +1 captures the market's first full reaction to results.

Historical price action around HTFL earnings shows significant volatility, with an average absolute Day 0 move of 5.56% and Day +1 move of 7.92%. The stock has demonstrated a tendency for sharp reactions, particularly on the day following results when investors have fully digested the report and management commentary.

The most recent earnings on May 14, 2026 saw modest Day 0 appreciation of 3.33% followed by a sharp -12.17% decline on Day +1, suggesting initial optimism gave way to disappointment after closer analysis. The March 2026 report produced the largest reaction with a 13.10% Day 0 surge and continued strength into Day +1. Earlier reports in November and September 2025 showed more muted Day 0 moves but still delivered meaningful Day +1 volatility.

The average Day 0 range of 9.06% and Day +1 range of 11.04% indicate HTFL typically experiences substantial intraday swings around earnings, reflecting the stock's relatively small float and the binary nature of investor reactions to execution updates from an emerging growth company. Investors should prepare for potential double-digit percentage moves in either direction.

Part 2.2: Options Market Expected Move

The options market is pricing a 13.10% expected move for HTFL through the August 21 expiration, implying a range of $25.94 to $33.76. This expected move is notably higher than the stock's average historical Day 0 move of 5.56% but roughly in line with the average Day +1 move of 7.92%, suggesting options traders are anticipating above-average volatility for this particular release.

Part 3: What Analysts Are Saying

Analyst sentiment on HeartFlow is decidedly bullish, with a consensus rating that translates to a Strong Buy. The current breakdown shows 8 Strong Buys, 0 Moderate Buys, 2 Holds, 0 Moderate Sells, and 0 Strong Sells among the 10 analysts covering the stock. This represents an improved sentiment trend, with one additional analyst upgrading to Strong Buy over the past month.

The average price target of $36.62 implies 22.7% upside from the current price of $29.85, with a range of $34.00 to $40.00 reflecting relatively tight conviction among analysts. The low-end target still suggests 13.9% upside, indicating even the most conservative analysts see meaningful appreciation potential. The high-end target of $40.00 represents 34.0% upside, suggesting some analysts believe HTFL could deliver substantial gains if execution continues to improve.

The strong analyst support reflects confidence in HTFL's commercial trajectory and improving financial profile. With 80% of analysts rating the stock a Strong Buy and sentiment improving recently, the analyst community appears to view current levels as an attractive entry point ahead of what they expect will be continued progress toward profitability. The tight clustering of price targets around $36-$37 suggests broad agreement on the company's near-term valuation potential.

Part 4: Technical Picture

HeartFlow's technical setup heading into earnings shows improving momentum after recent consolidation. The Barchart Technical Opinion currently registers a 16% Buy signal, representing a dramatic shift from the 56% Sell signal just one week ago and the 8% Sell reading from a month ago. This rapid reversal suggests technical indicators have turned decisively positive in the immediate run-up to earnings.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal indicates some near-term resistance despite recent strength, suggesting the stock may be approaching overbought conditions
• Medium-term (25% Buy): Modest buy signal reflects building positive momentum in the intermediate timeframe as the stock breaks above key moving averages
• Long-term (50% Buy): Moderate buy signal shows the longer-term trend has turned constructive, supporting the case for sustained appreciation

Trend Characteristics: The trend is showing Minimum strength but is Weakening, suggesting the recent rally may be vulnerable to profit-taking if earnings disappoint.

The stock is trading at $29.85, positioned above all major moving averages including the 5-day ($28.95), 10-day ($27.70), 20-day ($26.34), 50-day ($28.69), 100-day ($28.69), and 200-day ($28.87).

This alignment above all moving averages is technically constructive and indicates the stock has built a cushion of support heading into the release. However, with the current price just above the 50-day and 100-day averages at $28.69, HTFL has limited downside buffer before testing key support levels. The stock's position near the analyst consensus target of $36.62 suggests much of the near-term upside may already be reflected in the current price, making execution on earnings critical. The technical setup is cautiously supportive but leaves little room for disappointment, with the 20-day moving average at $26.34 representing the first major support level if results or guidance fall short of expectations.